GW Pharma (GWPH) plunged today before quickly recovering some of the losses following the release of an abstract of a study published to the American Epilepsy Society website in...
GW Pharmaceuticals and Otsuka Announce Results From Two Remaining Sativex(R) Phase 3 Cancer Pain Trials – Consistent with previously announced results from the initial Phase 3 trial, remaining trials...
GW Pharmaceuticals and the Government of New South Wales Announce a Strategic Agreement to Study Epidiolex(R) and CBDV in a Clinical Trial and Research Program for Children With...
BARCELONA — Multiple sclerosis patients taking the oromucosal cannabis-based spray called Sativex in routine practice to relieve spasticity are getting approximately the same degree of benefit expected from the...
GW Pharmaceuticals (NASDAQ: GWPH), at work on treatments derived from cannabis, is planning to expand its focus to schizophrenia after charting some positive signs in an exploratory trial. The company...
The stratospheric rise of medical marijuana as a possible recognized treatment for epilepsy, now underway, is an example of what can be achieved through the sharing of personal stories...
